
Yeztugo by Gilead Gets FDA OK, Promises Easier HIV Prevention
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults …